Sanofi (SNY)

44.07
0.82 1.80
NYSE : Health Technology
Prev Close 44.89
Open 44.03
Day Low/High 44.00 / 44.27
52 Wk Low/High 37.43 / 45.86
Volume 1.35M
Avg Volume 1.26M
Exchange NYSE
Shares Outstanding 2.58B
Market Cap 113.56B
EPS 1.70
P/E Ratio 24.27
Div & Yield 1.20 (2.83%)
The Hartford, Aetna Ink Tie-Up; All Eyes on Peanut Allergies -- ICYMI

The Hartford, Aetna Ink Tie-Up; All Eyes on Peanut Allergies -- ICYMI

Here's what you need to know now for Monday, Oct. 23.

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.

Flexion's Latest FDA Approval Reignites Takeover Chatter

Flexion's Latest FDA Approval Reignites Takeover Chatter

The Burlington, Mass.-based pharmaceutical firm on Oct. 6 secured approval from the Food and Drug Administration for its osteoarthritis knee pain treatment Zilretta, a non-opioid medicine.

Pfizer Consumer Unit Worth as Much as $14 Billion

Pfizer Consumer Unit Worth as Much as $14 Billion

A deal would give the company capital to do more deals but the decision also keeps the company's recently scratched plans to split into two separate companies alive. The division itself had about $3.4 billion in 2016 sales and houses brands such as Advil, Chaptstick, Centrum and Preparation H, among others.

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.

Robert Herjavec Predicts New Legislation in Response to the Equifax Hack

Robert Herjavec Predicts New Legislation in Response to the Equifax Hack

Shark Tank's Robert Herjavec on why the Equifax hack is different from others cyber attacks.

Alnylam And Sanofi Report Positive Topline Results From APOLLO Phase 3 Study Of Patisiran In Hereditary ATTR (hATTR) Amyloidosis Patients With Polyneuropathy

Alnylam And Sanofi Report Positive Topline Results From APOLLO Phase 3 Study Of Patisiran In Hereditary ATTR (hATTR) Amyloidosis Patients With Polyneuropathy

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the APOLLO Phase 3 study of...

Biotech Mailbag: Buy Dip in T2 Biosystems?

Biotech Mailbag: Buy Dip in T2 Biosystems?

Plus, what's going on with Lexicon Pharmaceuticals?

FDA Official Calls for Ending Codeine Use in Kids Cough Products

FDA Official Calls for Ending Codeine Use in Kids Cough Products

An FDA advisory panel recommends that warnings on cough syrups be extended from young children to everyone under 18.

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids

A small portion of the population is prone to "ultra-metabolize" codeine at rates far in excess of the general population.

Sanofi Has Good Potential Upside

Sanofi Has Good Potential Upside

I would buy strength above $50 and $51 in Sanofi.

European Pharma Companies Slip on MS Pricing Probe

European Pharma Companies Slip on MS Pricing Probe

House Democrats start probe into MS drug prices

Mylan Finalizes $465 Million EpiPen Settlement With DoJ

Mylan Finalizes $465 Million EpiPen Settlement With DoJ

The dispute became the center of a drug price firestorm.

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Teva said weak U.S. markets and the ongoing political turmoil in Venezuela weighed on the company's second quarter performance.

Sanofi Is Selling a Ton of Vaccines So It Decided to Hike Its Profit Outlook

Sanofi Is Selling a Ton of Vaccines So It Decided to Hike Its Profit Outlook

Sanofi is starting to offset diabetes franchise losses

Dow Scores Record Close as Retail Roars Higher, Walmart Rallies

Dow Scores Record Close as Retail Roars Higher, Walmart Rallies

Upbeat guidance from Target inspires retail rally.

Dow on Track for Record Close as Retail Roars Higher, Walmart Rallies

Dow on Track for Record Close as Retail Roars Higher, Walmart Rallies

Upbeat guidance from Target inspires retail rally.

Healthcare Stocks Sell Off, Retail Rallies on Upbeat Guidance From Target

Healthcare Stocks Sell Off, Retail Rallies on Upbeat Guidance From Target

Upbeat guidance from Target inspires retail rally.

Sanofi Steps Up M&A Activity With $650 Million Purchase of Protein Sciences

Sanofi Steps Up M&A Activity With $650 Million Purchase of Protein Sciences

Sanofi was also recently engaged in two other deals that it lost out on.

Alnylam And Sanofi Genzyme Report Positive Results From Ongoing Phase 2 Open-Label Extension Study With Investigational RNAi Therapeutic Fitusiran In Patients With Hemophilia A And B With Or Without Inhibitors

Alnylam And Sanofi Genzyme Report Positive Results From Ongoing Phase 2 Open-Label Extension Study With Investigational RNAi Therapeutic Fitusiran In Patients With Hemophilia A And B With Or Without Inhibitors

Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today new positive results from the ongoing...

Stocks Lower as Tech Losses Escalate, Senate Delays Its Healthcare Plan

Stocks Lower as Tech Losses Escalate, Senate Delays Its Healthcare Plan

Tech, healthcare slide weighs on rest of markets.

Senate Punts Vote on Healthcare Bill, Wall Street Fares Poorly

Senate Punts Vote on Healthcare Bill, Wall Street Fares Poorly

Healthcare's slide weighs on rest of markets.

Why Gilead Sciences Is Nearing Yet Another Mind-Bending Breakout

Why Gilead Sciences Is Nearing Yet Another Mind-Bending Breakout

The stock has been on fire.

Looking for Some Positive Spin

Breadth and volume should've been better.

Tesaro Stock Jumps on Sanofi, Gilead Takeover Interest

Tesaro Stock Jumps on Sanofi, Gilead Takeover Interest

If one of the two were to successfully acquire the company, it would get access to Zejula, a PARP inhibitor approved to treat women with ovarian cancer.

Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals

Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals

Plus more from the biotechnology world on Wednesday, June 7.

Sony Patent Infringement Claim Results in Investigation of FujiFilm Imports

Sony Patent Infringement Claim Results in Investigation of FujiFilm Imports

The magnetic tape cartridges in the company's products will be under review.

Symantec Fingers North Korea as Perpetrator Behind 'WannaCry' Ransomware Attacks

Symantec Fingers North Korea as Perpetrator Behind 'WannaCry' Ransomware Attacks

The cybersecurity firm deemed it 'highly likely' that a group of hackers working with North Korea was behind the attack.

Nevada Senate Passes Bill to Force Diabetes Drug Manufacturers to Disclose Pricing Practices

Nevada Senate Passes Bill to Force Diabetes Drug Manufacturers to Disclose Pricing Practices

The legislation would also force companies to announce planned price hikes.

Regeneron Shares Rise After Reporting Better-Than-Expected Sales

Regeneron Shares Rise After Reporting Better-Than-Expected Sales

The Tarrytown, N.Y.-based biopharmaceutical firm had first-quarter revenue of $1.32 billion.

TheStreet Quant Rating: B (Buy)